Published in PLoS One on January 17, 2013
The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives | NCT03291743
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis. Immunity (2015) 1.66
Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation. Tissue Barriers (2015) 1.02
Intestinal epithelium and autophagy: partners in gut homeostasis. Front Immunol (2013) 0.94
Giardia duodenalis cathepsin B proteases degrade intestinal epithelial interleukin-8 and attenuate interleukin-8-induced neutrophil chemotaxis. Infect Immun (2014) 0.84
The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. Fibrogenesis Tissue Repair (2013) 0.83
Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci Rep (2016) 0.77
Domino effect of hypomagnesemia on the innate immunity of Crohn's disease patients. World J Diabetes (2014) 0.75
Making sense of the cause of Crohn's - a new look at an old disease. F1000Res (2016) 0.75
Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2017) 0.75
The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. Cent Eur J Immunol (2016) 0.75
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol (2007) 16.21
Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 11.33
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 6.84
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol (2008) 6.09
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity (2009) 3.13
Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology (1997) 3.00
Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest (2001) 2.73
Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut (1992) 2.71
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut (2009) 2.48
Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol (1999) 2.38
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology (2002) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol (2008) 1.26
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut (2007) 1.18
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis (2007) 1.05
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology (2008) 0.93
Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut (1998) 0.92
T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond) (2010) 0.89
Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology (1997) 0.84
Th17-cytokine blockers as a new approach for treating inflammatory bowel disease. Ann Med (2010) 0.77
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 1.82
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.81
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol (2010) 1.66
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis (2011) 1.52
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc (2006) 1.46
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets (2008) 1.43
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis (2008) 1.34
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology (2007) 1.19
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis (2009) 1.18
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis (2007) 1.15
New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.15
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology (2007) 1.14
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther (2012) 1.13
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway. Proc Natl Acad Sci U S A (2008) 1.12
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol (2006) 1.11
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology (2002) 1.09
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol (2007) 1.08
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol (2012) 1.07
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol (2007) 1.06